MCID: ESP025
MIFTS: 38

Esophagus Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Esophagus Adenocarcinoma

MalaCards integrated aliases for Esophagus Adenocarcinoma:

Name: Esophagus Adenocarcinoma 12 15
Adenocarcinoma of Esophagus 43 71
Oesophageal Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4914
MeSH 43 C562730
NCIt 49 C4025
SNOMED-CT 67 276803003
UMLS 71 C0279628

Summaries for Esophagus Adenocarcinoma

Disease Ontology : 12 An esophageal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Esophagus Adenocarcinoma, also known as adenocarcinoma of esophagus, is related to barrett esophagus and adenocarcinoma. An important gene associated with Esophagus Adenocarcinoma is HNF1A-AS1 (HNF1A Antisense RNA 1), and among its related pathways/superpathways are MicroRNAs in cancer and Central carbon metabolism in cancer. The drugs Cisplatin and Cetuximab have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and t cells.

Related Diseases for Esophagus Adenocarcinoma

Diseases related to Esophagus Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 302)
# Related Disease Score Top Affiliating Genes
1 barrett esophagus 30.9 TP53 PTGS2 ERBB2 CDX2 AFAP1-AS1
2 adenocarcinoma 30.8 TP53 PTGS2 HNF1A-AS1 FGFR2 ERBB2 CDX2
3 signet ring cell adenocarcinoma 30.5 TP53 ERBB2 CDX2
4 atrophic gastritis 30.4 TP53 PTGS2 CDX2
5 gastritis 30.4 TP53 PTGS2 CDX2 ATP4A
6 tubular adenocarcinoma 30.3 MIR21 ERBB2 CDX2
7 in situ carcinoma 30.3 TP53 MIR143 ERBB2
8 exanthem 30.2 ERBB2 ATP4A ATP12A
9 active peptic ulcer disease 30.2 PTGS2 ATP4A ATP12A
10 peptic ulcer disease 30.2 TP53 PTGS2 ATP4A ATP12A
11 gastric adenocarcinoma 30.2 TP53 PTGS2 FGFR2 ERBB2 CDX2
12 barrett's adenocarcinoma 30.2 TP53 TAGLN2 PTGS2 ERBB2 COX7A2
13 squamous cell carcinoma 30.2 TP53 PTGS2 HNF1A-AS1 FGFR2 ERBB2
14 gastroesophageal reflux 30.1 TP53 PTGS2 CDX2 ATP4A ATP12A
15 pulmonary disease, chronic obstructive 30.0 MIR21 MIR199A1 ATP4A ATP12A
16 peptic esophagitis 30.0 PTGS2 CDX2 ATP4A ATP12A
17 bile reflux 30.0 PTGS2 CDX2 ATP4A ATP12A
18 colon adenocarcinoma 29.8 TP53 PTGS2 MIR21 ERBB2
19 body mass index quantitative trait locus 11 29.5 TP53 PTGS2 MIR21 MIR199A1 MIR196A1 MIR143
20 esophageal cancer 29.0 TP53 PTGS2 MIR330 MIR21 MIR199A1 MIR196A1
21 gastric cancer 28.7 TP53 PTGS2 MIR215 MIR21 MIR199A1 MIR196A1
22 colorectal cancer 27.8 TP53 PTGS2 MIR215 MIR21 MIR199A1 MIR196A1
23 rare head and neck tumor 10.6 TP53 FGFR2
24 vagus nerve disease 10.6 ATP4A ATP12A
25 bent bone dysplasia syndrome 10.6 FGFR2 ERBB2
26 hemangioma of intra-abdominal structure 10.5 ATP4A ATP12A
27 adult teratoma 10.5 TP53 FGFR2
28 acquired gastric outlet stenosis 10.5 ATP4A ATP12A
29 displacement of cardia through esophageal hiatus 10.5 ATP4A ATP12A
30 angiodysplasia of intestine 10.5 ATP4A ATP12A
31 benzylpenicillin allergy 10.5 ATP4A ATP12A
32 granulomatous gastritis 10.5 ATP4A ATP12A
33 bacterial esophagitis 10.5 ATP4A ATP12A
34 lingual goiter 10.5 ATP4A ATP12A
35 cascade stomach 10.5 ATP4A ATP12A
36 gastrojejunal ulcer 10.5 ATP4A ATP12A
37 median arcuate ligament syndrome 10.5 ATP4A ATP12A
38 laryngeal tuberculosis 10.5 ATP4A ATP12A
39 fungal esophagitis 10.5 ATP4A ATP12A
40 dieulafoy lesion 10.5 ATP4A ATP12A
41 esophagus melanoma 10.5 ATP4A ATP12A
42 emphysematous cholecystitis 10.5 ATP4A ATP12A
43 necrotizing gastritis 10.5 ATP4A ATP12A
44 cervix erosion 10.5 ATP4A ATP12A
45 her2-receptor positive breast cancer 10.5 MIR196A1 ERBB2
46 pneumatosis cystoides intestinalis 10.5 ATP4A ATP12A
47 gastric gastrinoma 10.5 ATP4A ATP12A
48 superior mesenteric artery syndrome 10.5 ATP4A ATP12A
49 chronic laryngitis 10.5 ATP4A ATP12A
50 wolffian duct adenocarcinoma 10.5 TP53 FGFR2

Graphical network of the top 20 diseases related to Esophagus Adenocarcinoma:



Diseases related to Esophagus Adenocarcinoma

Symptoms & Phenotypes for Esophagus Adenocarcinoma

Drugs & Therapeutics for Esophagus Adenocarcinoma

Drugs for Esophagus Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 115)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
2
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
3
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
4
Lansoprazole Approved, Investigational Phase 2, Phase 3 103577-45-3 3883
5
Theophylline Approved Phase 2, Phase 3 58-55-9 2153
6
Dexlansoprazole Approved, Investigational Phase 2, Phase 3 103577-45-3, 138530-94-6 9578005
7
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
8
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
9 Antineoplastic Agents, Immunological Phase 3
10 Tubulin Modulators Phase 3
11 Antimitotic Agents Phase 3
12 Respiratory System Agents Phase 2, Phase 3
13 Anti-Ulcer Agents Phase 2, Phase 3
14 Antacids Phase 2, Phase 3
15 Phosphodiesterase Inhibitors Phase 2, Phase 3
16 Anti-Asthmatic Agents Phase 2, Phase 3
17 Vasodilator Agents Phase 2, Phase 3
18 Gastrointestinal Agents Phase 2, Phase 3
19 Proton Pump Inhibitors Phase 2, Phase 3
20 Bronchodilator Agents Phase 2, Phase 3
21 Neurotransmitter Agents Phase 2, Phase 3
22 Pharmaceutical Solutions Phase 3
23 Albumin-Bound Paclitaxel Phase 3
24
Epirubicin Approved Phase 2 56420-45-2 41867
25
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
26
Trioxsalen Approved Phase 2 3902-71-4 5585
27
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
28
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
29
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
30
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
31
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
32
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
33
Melphalan Approved Phase 2 148-82-3 460612 4053
34
Lenograstim Approved, Investigational Phase 2 135968-09-1
35
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
36
Pertuzumab Approved Phase 2 380610-27-5, 145040-37-5 2540
37
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
38
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
39
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
40
Itraconazole Approved, Investigational Phase 2 84625-61-6 55283
41
Capecitabine Approved, Investigational Phase 1, Phase 2 154361-50-9 60953
42
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
43
Fluorouracil Approved Phase 2 51-21-8 3385
44
leucovorin Approved Phase 2 58-05-9 6006 143
45
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
46
Pancrelipase Approved, Investigational Phase 2 53608-75-6
47
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
48
Hydroxyurea Approved Phase 2 127-07-1 3657
49
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
50
Alvocidib Experimental, Investigational Phase 2 131740-09-5, 146426-40-6 5287969

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 A PROSPECTIVE RANDOMISED NON SURGICAL TREATMENT OF OESOPHAGEAL CANCER WITH COMBINED CHEMOTHERAPY AND EXTERNAL BEAM IRRADIATION WITH VS WITHOUT HIGH-DOSE BRACHYTHERAPY Unknown status NCT00002884 Phase 3 chemotherapy;cisplatin;fluorouracil
2 A PHASE III INTERGROUP RANDOMIZED COMPARISON OF COMBINED MODALITY THERAPY FOR CARCINOMA OF THE ESOPHAGUS: HIGH-DOSE VS CONVENTIONAL-DOSE RADIATION THERAPY Completed NCT00002631 Phase 3 chemotherapy;cisplatin;fluorouracil
3 The Evaluation of Effectiveness Between Empirical and Guided Therapy for Unexplained Non-Cardiac Chest Pain Completed NCT03319121 Phase 2, Phase 3 Empirical therapy group;Guided therapy group
4 Randomised Phase III Study of Docetaxel vs Active Symptom Control in Patients With Relapsed Oesophago-gastric Adenocarcinoma Completed NCT00978549 Phase 3 docetaxel;steroid therapy
5 A Prospective Randomized Phase III Trial Comparing Trimodality Therapy (Cisplatin, 5-FU, Radiotherapy, and Surgery) to Surgery Alone for Esophageal Cancer Completed NCT00003118 Phase 3 cisplatin;fluorouracil
6 Multimodal Therapy With and Without Cetuximab in Patients With Locally Advanced Esophageal Carcinoma - An Open-Label Phase III Trial Completed NCT01107639 Phase 3 cisplatin;docetaxel
7 Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus Active, not recruiting NCT02509286 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
8 A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Patients With Advanced Esophageal Cancer Unknown status NCT00003326 Phase 2 paclitaxel
9 The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma. Unknown status NCT00674167 Phase 2 Docetaxel;Cisplatin;Capecitabine
10 Esophageal Cancer: A Phase II Study of Paclitaxel, Carboplatin and 5-Fluorouracil With Simultaneous Radiotherapy Followed by Surgical Resection Unknown status NCT00006472 Phase 2 carboplatin;fluorouracil;paclitaxel
11 Pre-operative Epirubicin, Capecitabine (Xeloda) and Cisplatin in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma Completed NCT00220103 Phase 2 epirubicin, capecitabine, cisplatin
12 Phase II Trial of Cetuximab, Irinotecan, Cisplatin (CPC), Concurrent Radiation Therapy, and Surgery for Resectable Esophageal Cancer Completed NCT00165490 Phase 2 Cetuximab;Cisplatin;Irinotecan
13 Endoscopic Therapy of Early Cancer in Barretts Esophagus Completed NCT00217087 Phase 2
14 A Phase II Study of Neoadjuvant Therapy With Cisplatin, Docetaxel, Panitumumab Plus Radiation Therapy Followed by Surgery in Patients With Locally Advanced Adenocarcinoma of the Distal Esophagus Completed NCT00757172 Phase 2 cisplatin;docetaxel
15 A Phase II Study of Doxorubicin, Cisplatin, and 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus Completed NCT00165191 Phase 2 Doxorubicin;Cisplatin;5-fluorouracil
16 Phase II Trial of Flavopiridol and Paclitaxel in Patients With Paclitaxel-Refractory Esophageal Cancer Completed NCT00006245 Phase 2 alvocidib;paclitaxel
17 Phase II Single-Arm Trial Of CPT-11 (Irinotecan HC1; Camptosar Injection)/Cisplatin In Patients With Advanced Esophageal Cancer Completed NCT00030862 Phase 2 cisplatin;irinotecan hydrochloride
18 Gemcitabine Plus Irinotecan in Patients With Esophageal Cancer, Phase II Completed NCT00012363 Phase 2 gemcitabine hydrochloride;irinotecan hydrochloride
19 A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach Completed NCT00985192 Phase 2 everolimus
20 Phase II Trail of Bryostatin-1 and Paclitaxel in Patients With Advanced Esophageal Cancer Completed NCT00005599 Phase 2 bryostatin 1;paclitaxel
21 A Phase II Multicenter Study of the Efficacy and Safety Study of PNU-93914 (Liposome Encapsulated Paclitaxel) in Patients With Advanced Esophageal Cancer Previously Exposed to Chemotherapy Completed NCT00016900 Phase 2 liposomal paclitaxel
22 Phase II Trial of Preoperative Combined Modality Therapy for Localized Esophageal Carcinoma: Cisplatin-Paclitaxel Followed by Radiation Therapy With Concurrent Cisplatin and Paclitaxel Completed NCT00003087 Phase 2 cisplatin;paclitaxel
23 An Open-label, Multicenter Phase II Trial of Sunitinib for Patients With Chemo-refractory Metastatic Gastric Cancer Completed NCT00411151 Phase 2 Sunitinib-Malate
24 A Phase II Trial of Preoperative Radiation and Chemotherapy (Paclitaxel, Carboplatin, and Continuous Infusion 5-FU) for Locally Advanced Esophageal Cancer Completed NCT00022139 Phase 2 carboplatin;fluorouracil;paclitaxel
25 Phase II Evaluation Of Paclitaxel, Cisplatin And 5-Fluorouracil Given In Combination With Radiation Therapy Prior To Surgery In Patients With Resectable Esophageal Cancer Completed NCT00021320 Phase 2 cisplatin;fluorouracil;paclitaxel
26 A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (With the Potential for Crossover) for Elderly and/or Poor Performance Status Patients With Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction Completed NCT00891878 Phase 2 capecitabine;sunitinib malate
27 Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer Completed NCT00381706 Phase 2 ECF;IC;FOLFOX
28 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
29 Non-Operative Therapy Of Local-Regional Carcinoma Of The Esophagus: A Randomizd Phase II Study Of Two Paclitaxel-Based Chemoradiotherapy Regimens Completed NCT00009880 Phase 2 cisplatin;fluorouracil;paclitaxel
30 A Phase II Trial of Induction Chemotherapy With Epirubicin, Oxaliplatin and Fluorouracil (EOF) Followed by Esophagogastrectomy and Post-operative Concurrent Chemoradiotherapy With Fluorouracil and Cisplatin, in Patients With Loco-regionally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction and Gastric Cardia Completed NCT00601705 Phase 2 cisplatin;epirubicin hydrochloride;fluorouracil;oxaliplatin
31 Randomized Phase II Trial of Extended Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia Completed NCT00938470 Phase 2 capecitabine;docetaxel;fluorouracil;oxaliplatin
32 Paclitaxel Combined With 5-FU and Cisplatin Concomitant With Radiotherapy in the Management of Locally Advanced or Metastatic Esophageal Cancer (Adenocarcinoma and Squamous Histologies) - A Phase I/Modified Phase II Trial Completed NCT00002984 Phase 1, Phase 2 cisplatin;fluorouracil;paclitaxel
33 A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer Completed NCT01498289 Phase 2 FOLFOX regimen;docetaxel;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
34 INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL Recruiting NCT02205047 Phase 2 Cisplatin;5-fluorouracil or Capecitabine;Trastuzumab;Pertuzumab
35 Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer (ICONIC Trial) Recruiting NCT03399071 Phase 2 FLOT-A
36 A Phase II Trial Evaluating the Effectiveness of Itraconazole in Improving Pathologic Complete Response Rates in Patients With Esophageal Cancer Through Inhibition of the Hedgehog and AKT Signaling Pathways Recruiting NCT04018872 Phase 2 Itraconazole
37 Phase 1/2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer Active, not recruiting NCT02735239 Phase 1, Phase 2 Durvalumab;Tremelimumab;Oxaliplatin;Capecitabine;Paclitaxel;Carboplatin;5-fluorouracil (5-FU);Leucovorin;docetaxel
38 Multi-Modality Treatment of Resectable Oesophageal Adenocarcinoma Using Peri-operative Chemotherapy With Additional Pre-operative Combined Radiotherapy and Cetuximab Terminated NCT00827671 Phase 2 cetuximab
39 A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin Terminated NCT00012246 Phase 2
40 PFL-Alpha Chemotherapy Followed by Surgery or FHX for Early Stage Esophageal Cancer - A Pilot Project Terminated NCT00004897 Phase 2 cisplatin;fluorouracil;hydroxyurea;leucovorin calcium
41 Effect of Zinc on Barrett's Metaplasia Unknown status NCT01984580 Phase 1 zinc gluconate
42 A Pilot Study of Tamoxifen in Oesophageal Cancer Unknown status NCT02513849 Phase 1 Tamoxifen
43 A Pilot Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus Completed NCT01238042 Phase 1 HPPH
44 Phase I Trial of Combined Modality Irinotecan, Cisplatin, and Concurrent Radiation Therapy for Patients With Locally Advanced Esophageal Cancer Completed NCT00005638 Phase 1 cisplatin;irinotecan hydrochloride
45 A Phase I Study of Oxaliplatin in Combination With Continuous Infusion 5-Fluorouracil and Radiation in Esophageal Cancer Completed NCT00004257 Phase 1 fluorouracil;oxaliplatin
46 A PHASE I TRIAL OF COMBINED MODALITY THERAPY FOR LOCALIZED ESOPHAGEAL CANCER: CISPLATIN-PACLITAXEL FOLLOWED BY RADIATION THERAPY WITH CONCURRENT CISPLATIN AND ESCALATING DOSES OF PACLITAXEL Completed NCT00002711 Phase 1 chemotherapy;cisplatin;paclitaxel
47 Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (VORINOSTAT)] With Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (FOLFIRI) for Advanced Upper Gastrointestinal Cancers Completed NCT00537121 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium;vorinostat
48 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
49 Phase I Pharmacology Study Of Oral And Intravenous BCX-1777 In Patients With Refractory T-Cell And Non-T-Cell Malignancies Completed NCT00073944 Phase 1 forodesine hydrochloride
50 A Phase I Trial of Irinotecan, Radiation Therapy and Escalating Doses of Docetaxel With Cisplatin in Locally Advanced Esophageal Cancer Completed NCT00601692 Phase 1 cisplatin;docetaxel;irinotecan hydrochloride

Search NIH Clinical Center for Esophagus Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma of esophagus

Genetic Tests for Esophagus Adenocarcinoma

Anatomical Context for Esophagus Adenocarcinoma

MalaCards organs/tissues related to Esophagus Adenocarcinoma:

40
Liver, Testes, T Cells, Lung, Breast, Bone, Lymph Node

Publications for Esophagus Adenocarcinoma

Articles related to Esophagus Adenocarcinoma:

(show top 50) (show all 98)
# Title Authors PMID Year
1
MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. 46
20301167 2010
2
Clinical profile of patients presenting with dysphagia - an experience from a tertiary care center in North India. 61
32514456 2020
3
Current Status of Mucosal Imaging with Narrow-Band Imaging in the Esophagus. 61
32307976 2020
4
Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus. 61
31664618 2020
5
Impact of Lymphadenectomy on Survival After Unimodality Transthoracic Esophagectomy for Adenocarcinoma of Esophagus. 61
31605326 2020
6
Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies. 61
31748258 2020
7
Size and Importance of Socioeconomic Status-Based Disparities in Use of Surgery in Nonadvanced Stage Gastrointestinal Cancers. 61
31605347 2020
8
Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis. 61
31619265 2019
9
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. 61
31036088 2019
10
Allergies and the Subsequent Risk of Cancer among Elderly Adults in the United States. 61
30700443 2019
11
Desmoplasia and Detached Papillae in Early Esophageal Adenocarcinoma: A Histologic Study on Endoscopic Submucosal Dissection Specimens. 61
31019616 2019
12
A Randomized Placebo-Controlled N-of-1 Trial: The Effect of Proton Pump Inhibitor in the Management of Gastroesophageal Reflux Disease. 61
31929980 2019
13
A six-microRNA signature can better predict overall survival of patients with esophagus adenocarcinoma. 61
31380150 2019
14
Barrett's Esophagus in Patients with Gastroesophageal Reflux Disease. 61
29983427 2018
15
The arachidonic acid metabolism protein-protein interaction network and its expression pattern in esophageal diseases. 61
29636881 2018
16
Histopathological Assessment for Esophageal Adenocarcinoma. 61
29600360 2018
17
Obesity and Cancer: Evidence, Impact, and Future Directions. 61
29038151 2018
18
Preliminary evaluation for Bit1 as a potential biomarker for squamous cell carcinoma and adenocarcinoma of esophagus. 61
28488526 2017
19
The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma. 61
28184414 2017
20
C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis. 61
27636117 2017
21
Epigenetic regulation on the gene expression signature in esophagus adenocarcinoma. 61
28049580 2017
22
Oral squamous cell cancer protein-protein interaction network interpretation in comparison to esophageal adenocarcinoma. 61
28744358 2017
23
Racial Differences in Esophageal Squamous Cell Carcinoma: Incidence and Molecular Features. 61
28393072 2017
24
The different functions and clinical significances of caveolin-1 in human adenocarcinoma and squamous cell carcinoma. 61
28243118 2017
25
[The molecular genetic alterations in mucosa of intestines as markers of oncologic progression and estimate of effectiveness of anti-reflux operations in patients with Barrett's esophagus]. 61
30615323 2016
26
Detection of human papillomavirus DNA in gastric carcinoma specimens in a high-risk region of Iran. 61
27588180 2016
27
Trajectory of body shape across the lifespan and cancer risk. 61
26704725 2016
28
Four Synchronous Primary Malignancies of the Breast, Lung, Colon and Esophagus. 61
26504043 2015
29
Simultaneous Esophageal Squamous Cell Carcinoma and Adenocarcinoma: A Case Report. 61
26609356 2015
30
Predictive Value of the Neutrophil/Lymphocyte Ratio in Peritoneal and/or Metastatic Disease at Staging Laparoscopy for Gastric and Esophageal Adenocarcinoma. 61
25952408 2015
31
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. 61
25947566 2015
32
Analysis of AC3-33 gene expression in multiple organ cancer and adjacent normal tissue by RNA in situ hybridization. 61
26137149 2015
33
In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. 61
24708360 2015
34
Four cases of adenocarcinoma of esophagus with co-existing hydatid cyst of liver which caused delayed management of carcinoma esophagus. 61
24869991 2015
35
Prolonged Impacted Denture in the Esophagus: A Case Report and Review of the Literature. 61
27162898 2015
36
Unusual metastasis of esophageal cancer. 61
25518280 2014
37
Esophagus adenocarcinoma in a young patient with celiac disease; Is celiac disease a predisposing factor for esophagus adenocarcinoma as well as squamous cell carcinoma? 61
26185881 2014
38
Research on the typical miRNA and target genes in squamous cell carcinoma and adenocarcinoma of esophagus cancer with DNA microarray. 61
24519530 2014
39
OCT3 and SOX2 promote the transformation of Barrett's esophagus to adenocarcinoma by regulating the formation of tumor stem cells. 61
24481676 2014
40
Radiotherapy in the multimodality management of esophageal cancer. 61
25799618 2014
41
Esophagogastric metaplasia relates to nodal metastases in adenocarcinoma of esophagus and cardia. 61
23434259 2013
42
MUTYH association with esophageal adenocarcinoma in a Han Chinese population. 61
24377542 2013
43
Increase of epidermal growth factor receptor expression in progression of GERD, Barrett, and adenocarcinoma of esophagus. 61
22875307 2013
44
Aberrant expression of Wnt and Notch signal pathways in Barrett's esophagus. 61
22889748 2012
45
Association of methylenetetrahydrofolate reductase C677T-A1298C polymorphisms with risk for esophageal adenocarcinoma, Barrett's esophagus, and reflux esophagitis. 61
21951971 2012
46
Comparative evaluation of serum C-reactive protein (CRP) levels in the different histological subtypes of esophageal cancer (squamous cell carcinoma and adenocarcinoma of esophagus). 61
22467322 2012
47
Hedgehog signaling activation in the development of squamous cell carcinoma and adenocarcinoma of esophagus. 61
22509480 2012
48
Endoscopic imaging in Barrett's esophagus: current practice and future applications. 61
24714225 2012
49
Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus. 61
22057498 2011
50
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. 61
21166737 2011

Variations for Esophagus Adenocarcinoma

Expression for Esophagus Adenocarcinoma

Search GEO for disease gene expression data for Esophagus Adenocarcinoma.

Pathways for Esophagus Adenocarcinoma

Pathways related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.77 TP53 PTGS2 MIR330 MIR215 MIR21 MIR199A1
2 10.98 TP53 FGFR2 ERBB2
3 10.27 MIR199A1 MIR145

GO Terms for Esophagus Adenocarcinoma

Biological processes related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 PTGS2 MIR21 FGFR2 ERBB2 CDX2
2 sodium ion export across plasma membrane GO:0036376 9.55 ATP4A ATP12A
3 cellular potassium ion homeostasis GO:0030007 9.54 ATP4A ATP12A
4 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.52 ATP4A ATP12A
5 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.5 MIR21 MIR199A1 MIR145
6 mesodermal cell differentiation GO:0048333 9.49 MIR145 FGFR2
7 angiotensin-activated signaling pathway GO:0038166 9.48 MIR145 MIR143
8 aorta smooth muscle tissue morphogenesis GO:0060414 9.46 MIR145 MIR143
9 negative regulation of interleukin-21 biosynthetic process GO:0045391 9.43 MIR215 MIR21
10 regulation of ERK1 and ERK2 cascade GO:0070372 9.43 MIR145 FGFR2 ERBB2
11 negative regulation of interleukin-21 production GO:0032705 9.4 MIR215 MIR21
12 regulation of phenotypic switching GO:1900239 9.37 MIR145 MIR143
13 positive regulation of protein kinase B signaling GO:0051897 9.35 MIR21 MIR199A1 MIR143 FGFR2 ERBB2
14 gene silencing by miRNA GO:0035195 9.23 MIR362 MIR330 MIR215 MIR21 MIR199A1 MIR196A1
15 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.16 MIR145 MIR143

Molecular functions related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 9.26 ATP4A ATP12A
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR362 MIR330 MIR215 MIR21 MIR199A1 MIR196A1
3 potassium-transporting ATPase activity GO:0008556 9.16 ATP4A ATP12A
4 potassium:proton exchanging ATPase activity GO:0008900 8.96 ATP4A ATP12A

Sources for Esophagus Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....